Asset profile
RP1
Biologic (subtype unspecified)
Evidence outlook
Mid-stage studies underway, no completed readout
Phase 2 studies are registered but none has completed a readout, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.
Also in development:Melanoma · Phase 2
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
72 competitors in this universe: 5 direct rivals (same mechanism and indication), 3 same-class, 64 same-indication; 65 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| RP1: this drug | Phase 2 | Biologic (subtype unspecified) | No discrete molecular target | ||
| Olvimulogene Nanivacirepvec | Phase 3 | Oncolytic Virus | No discrete molecular target | ||
| LN-145 | Phase 2 | Cell therapy | No discrete molecular target | ||
| KB707 | Phase 1/2 | Gene therapy / editing | No discrete molecular target | ||
| SL-28 | Phase 1/2 | Biologic (subtype unspecified) | No discrete molecular target | ||
| KB-GDT-01 | Phase 1 | Biologic (subtype unspecified) | No discrete molecular target | ||
| ALF201 | Phase 2 | Cell therapy | No discrete molecular target | ||
| Adipose-Derived MSC Clusters (S.Biomedics) | Phase 1/2 | Cell therapy | No discrete molecular target | ||
| BGC101 | Phase 1/2 | Cell therapy | No discrete molecular target | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR |
…and 57 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Compare head-to-head
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2028 (2)
2029 (2)
July 2029 (1)
What to watch
October 2029 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.